Form 4: Collegium Pharmaceutical Director Receives Stock Grant

Rita J. Balice-Gordon, a director at Collegium Pharmaceutical, received a grant of restricted stock units representing a contingent right to receive 9,791 shares of common stock.

Summary

• Rita J. Balice-Gordon, a director of Collegium Pharmaceutical, Inc. (COLL), has reported a transaction involving the acquisition of securities.
• On May 15, 2025, Ms. Balice-Gordon was granted 9,791 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon the director's continued service.
• The RSUs will be settled on the vesting date, or earlier upon the director's election, at the end of the director's service, death, disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
• Following the reported transaction, Ms. Balice-Gordon beneficially owns 56,279 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating confidence in the director's continued service and the company's future performance. It's a neutral to slightly positive signal.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and value creation.

Future Outlook

The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies as part of executive and director compensation packages. These grants are designed to align the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, and other equity-based awards.
• The vesting schedule and terms of these grants are generally comparable to those offered by similar companies in the pharmaceutical industry to attract and retain qualified board members.
• Companies like Teva Pharmaceutical, Mylan (now Viatris), and Endo International also utilize equity-based compensation for their directors.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning the director's interests with the company's long-term success.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

restricted stock units, director compensation, beneficial ownership, Form 4, Collegium Pharmaceutical, RSUs, stock grant, insider transaction